SI
EPZM

Sofinnova Investments’s Epizyme, Inc EPZM Stock Holding History

Sofinnova Investments’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-563,655
Closed -$3.47M – 75
2018
Q4 		$3.47M Buy
563,655
+272,337
+93% +$2.08M 0.43% 44
2018
Q3 		$3.09M Buy
+291,318
New +$3.33M 0.28% 48

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Sofinnova Investments's EPZM Position: Q1 2019 in Review

Sofinnova Investments sold out of Epizyme, Inc (EPZM) in Q1 2019, closing a stake of 563,655 shares — an estimated $3.47M sold.

Sofinnova Investments first reported a position in EPZM in Q3 2018 and held it in 2 quarters. The position peaked at $3.47M in Q4 2018. 121 funds tracked by Wall St. Rank hold EPZM as of Q1 2019.

  • Sofinnova Investments reported no remaining Epizyme, Inc position as of Q1 2019 after selling out during the quarter.
  • Sofinnova Investments sold 563,655 Epizyme, Inc shares in Q1 2019, an estimated $3.47M.
  • Sofinnova Investments first reported a position in Epizyme, Inc in Q3 2018 and held it in 2 quarters.
  • Sofinnova Investments's Epizyme, Inc position peaked at $3.47M in Q4 2018.
  • 121 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2019.

Based on Sofinnova Investments's 13F filing for Q1 2019, filed 15 May 2019.